Shield Therapeutics (STX) RNS Announcements

Add to Alert list
Date Time Source Announcement
11 Sep 2024 12:25 PM
EQS
Hardman & Co Research on Shield Therapeutics ...
04 Sep 2024 07:00 AM
RNS
Interim results
27 Aug 2024 07:00 AM
RNS
ACCRUFeR® Approved by Health Canada
14 Aug 2024 07:00 AM
RNS
Notice of interim results
24 Jul 2024 07:01 AM
RNS
Unaudited Q2 2024 Trading Update
24 Jul 2024 07:00 AM
RNS
Directorate Change
03 Jul 2024 07:00 AM
RNS
$5.7m Milestone Monetization Agreement with AOP
20 Jun 2024 04:25 PM
RNS
Results of 2024 Annual General Meeting
28 May 2024 07:00 AM
RNS
New Drug Application for Accrufer® in South Korea
23 May 2024 07:15 AM
EQS
Hardman & Co: Shield Therapeutics (STX): Cash...
10 May 2024 03:30 PM
RNS
Audited results for the year ended 31 Dec 2023
30 Apr 2024 07:00 AM
RNS
Business Update for Q1 2024
16 Apr 2024 07:00 AM
RNS
Notice of Results
21 Feb 2024 07:00 AM
RNS
Unaudited Full Year Trading Update
09 Jan 2024 07:00 AM
RNS
Appointment of new Chief Financial Officer
07 Dec 2023 07:00 AM
RNS
Q3 2023 U.S. Commercial Highlights
27 Nov 2023 05:24 PM
RNS
PDMR Transaction Notification
15 Nov 2023 07:30 AM
EQS
Hardman & Co Research on Shield Therapeutics ...
20 Oct 2023 11:45 AM
RNS
Abstract to be presented at Healthcare Conference
12 Oct 2023 07:00 AM
RNS
Chief Financial Officer Transition
03 Oct 2023 03:00 PM
RNS
Result of REX Retail Offer
03 Oct 2023 07:00 AM
RNS
Block listing Interim Return
03 Oct 2023 07:00 AM
RNS
Completion of SWK Financing
28 Sep 2023 12:50 PM
RNS
Successful completion of US$6.1m Equity Fundraise
28 Sep 2023 07:02 AM
RNS
REX Retail Offer
28 Sep 2023 07:01 AM
RNS
$20m secured debt facility &proposed equity raise
28 Sep 2023 07:00 AM
RNS
Interim results update and business update
06 Sep 2023 07:00 AM
RNS
Notice of Results and Change in reporting currency
25 Jul 2023 09:45 AM
EQS
Hardman & Co Research on Shield Therapeutics ...
24 Jul 2023 02:27 PM
RNS
Holding(s) in Company
20 Jul 2023 07:00 AM
RNS
Business Update and U.S. Q2 2023 Highlights
28 Jun 2023 05:30 PM
RNS
Results of 2023 Annual General Meeting
06 Jun 2023 10:10 AM
RNS
Grant of share options to the CEO
01 Jun 2023 11:00 AM
RNS
Holding(s) in Company
01 Jun 2023 10:55 AM
RNS
Holding(s) in Company
31 May 2023 07:00 AM
RNS
Total Voting Rights
19 May 2023 07:00 AM
RNS
2022 Annual Report and 2023 AGM Notice
18 May 2023 03:15 PM
RNS
Form 8 (OPD) - Shield Therapeutics plc
17 May 2023 07:15 AM
EQS
Hardman & Co Research on Shield Therapeutics ...
09 May 2023 04:00 PM
RNS
Rule 2.9 Announcement and TVR Update
27 Apr 2023 07:00 AM
RNS
Business Update and Unaudited Results
12 Apr 2023 07:00 AM
RNS
Notice of Results
05 Apr 2023 07:00 AM
RNS
Appointment of Chief Commercial Officer
31 Mar 2023 07:00 AM
RNS
Block Listing 6 Monthly Return
15 Mar 2023 04:35 PM
RNS
Price Monitoring Extension
28 Feb 2023 07:00 AM
RNS
Total Voting Rights Update
17 Feb 2023 11:05 AM
RNS
Second Price Monitoring Extn
17 Feb 2023 11:00 AM
RNS
Price Monitoring Extension
09 Feb 2023 04:40 PM
RNS
Second Price Monitoring Extn
09 Feb 2023 04:35 PM
RNS
Price Monitoring Extension
UK 100

Latest directors dealings